NASDAQ · LGND
Ligand Pharmaceuticals Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for LGND has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $2.15 | $2.25 | $2.08 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · MarketBeat · The Motley Fool- Fintel · Oct 29, 1:51 PM EDTLigand Reports Third Quarter 2026 Financial ResultsLigand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2026. Total revenues and income for the third quarter of 2026 were $78.7 million, compared with $115.5 million for the prior-year period, representing a decrease of 32
- RTTNews · Sep 24, 7:48 AM EDTLigand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy(RTTNews) – Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for upto $47 million, helping advance the latter's pipeline, which includes AVC-201 for the treatment of relapsed/refr
- RTTNews · Sep 22, 9:17 AM EDTLigand Buys Royalty Rights In Santen's Ryjunea Eye Drug(RTTNews) – Ligand Pharmaceuticals Inc. (LGND), announced on Tuesday that it has acquired royalty and milestone payment rights tied to Santen Pharmaceutical Co. Ltd's Ryjunea, the first approved pharmacologic treatment in Europe and the UK to slow myopia progression in children.
- MarketBeat · Aug 26, 1:02 PM EDTLigand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital3 Overlooked Stocks Positioned for the Next Market RotationLigand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and plann
- The Motley Fool · Aug 13, 9:13 AM EDTLigand (LGND) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 5:03 PM EDTLigand Pharmaceuticals Q2 Earnings Call Highlights3 Overlooked Stocks Positioned for the Next Market RotationLigand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 millio
- BNK Invest · Jul 20, 6:13 AM EDTLigand Pharmaceuticals Reaches Analyst Target PriceIn recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $301.78, changing hands for $303.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down
- MarketBeat · Jul 13, 8:35 AM EDT3 Overlooked Stocks Positioned for the Next Market RotationTech has carried this market for years, but it isn't the only game left running. Small caps are outperforming in 2026, the Magnificent Seven have cooled, and money is starting to spread into corners of the market that retail investors rarely check. Healthcare, insurance and regi
- Barchart · Jun 23, 2:49 PM EDTStocks Mostly Lower on Weakness in Megacap Tech and Software StocksThe S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.19%. September E-mini S&P futures (ESU26 ) fell -0.34%, and September E-mini Nasdaq futures…
- RTTNews · Jun 23, 4:54 AM EDTLigand Prices Upsized $625 Million Convertible Senior Notes Offering(RTTNews) – Ligand Pharmaceuticals Incorporated (LGND) announced the pricing of an upsized $625 million offering of 0.0% convertible senior notes due 2031 in a private placement to qualified institutional buyers, strengthening the company's financial flexibility and supporting it
- Barchart · Jun 22, 7:36 PM EDTStocks Supported by Strength in Chipmakers and AI-Infrastructure StocksThe S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.50%. September E-mini S&P futures (ESU26 ) are up +0.20%, and September E-mini Nasdaq futures…
- Barchart · Jun 22, 5:40 PM EDTStocks Erase Early Gains as Alphabet and Software Companies FallThe S&P 500 Index ($SPX ) (SPY ) today is down -0.40%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. September E-mini S&P futures (ESU26 ) are down -0.38%, and September E-mini Nasdaq futures…
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Ligand Pharmaceuticals Incorporated from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.